Clinical Trial Update: Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating a combination including filgrastim, cladribine, cytarabine, and mitoxantrone in newly diagnosed or relapsed/refractory acute myeloid …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Cladribine (cladribine)
• Filgrastim (filgrastim)
• Mitoxantrone (mitoxantrone)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Acute Biphenotypic Leukemia, de Novo Myelodysplastic Syndrome | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-06-26